Christopher Gerard - Jul 1, 2021 Form 4 Insider Report for AMEDISYS INC (AMED)

Role
President & COO
Signature
/s/ Jennifer R. Guckert, pursuant to a power of attorney
Stock symbol
AMED
Transactions as of
Jul 1, 2021
Transactions value $
-$313,622
Form type
4
Date filed
7/6/2021, 04:01 PM
Previous filing
Jun 3, 2021
Next filing
Aug 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMED Common Stock Sale -$238K -950 -2.35% $250.78 39.4K Jul 1, 2021 Direct F1, F2
transaction AMED Common Stock Sale -$75.4K -300 -0.76% $251.27 39.1K Jul 1, 2021 Direct
holding AMED Common Stock 279 Jul 1, 2021 Through 401(k) Plan F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.23 to $251.10, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The information in this report is based on a plan statement dated as of March 31, 2021.